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Abstract
Background: Febrile neutropenia (FN) is generally a complication of  cancer chemotherapy.
Objective: We retrospectively evaluated the febrile neutropenia episodes and their outcomes with respect to modification
rates of non-carbapenem-based empirical antibacterial therapy and vancomycin-resistant enterococcus (VRE) colonisation
that caused to VRE bacteremia in patients with hematological malignancies.
Methods: All consecutive patients, who were older than 14 years of age and developed febrile neutropenia episodes due to
hematological malignancies from September 2010 to November 2011 at the hematology department were included into the
study.
Results: In total, 86 consecutive neutropenic patients and their 151 febrile episodes were evaluated. The mean MASCC
prognostic index score was 18,72 ± 9,43. Among 86 patients, 28 patients experienced a total of 30 bacteremia episodes of
bacterial origin. Modification rates of both, empirical monotherapy and combination therapies, were found similar, statistically (P =
0,840).
Conclusion: Our results suggest that initiating of  non-carbapenem based therapy does not provide high response rates in
the treatment of febrile neutropenia attacks. Furthermore, non-carbapenem-based empirical therapy provides benefit in
regard to cost-effectiveness and antimicrobial stewardship when local antibiotic resistance patterns of gram-negative bacteria
are considered. Patients who are colonized with VRE are more likely to develop bacteremia with VRE strains as a result of  invasive
procedures and severe damage of mucosal barriers observed in this group of patients.
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Introduction
Febrile neutropenia (FN) is generally a complication
of cancer chemotherapy1, 2. Multinational Association
of Supportive Care in Cancer (MASCC) prognostic
index indicates that mortality is as low as 3% if the
MASCC score is >21, but as high as 36% if the
MASCC score is <153. Patients with bacteremia are
more likely to have a poor prognosis with mortality
rates of 18% with gram-negative bacteremia and
5% with gram-positive bacteremia. Among gram-
positive bacteria, bacteremia due to coagulase-
negative staphylococci has been shown to cause to
low mortality, enterococci to moderate mortality, and
Staphylococcus aureus to high mortality4. Mortality related
with FN has been steadily decreasing with the
implementation of guidelines, new laboratory tests
and serial computed tomography (CT) scanning, with
overall mortality rates ranging from as low as 5% in
patients with solid tumors (1% in low-risk patients)
to as high as 11% in some hematological
malignancies5. Empirical antibacterial therapy should
contain an anti-pseudomonal antimicrobial agent
which must be chosen according to cumulative local
antimicrobial resistance data. Although carbapenems
are recommended as empirical antibiotic therapy
options in febrile patients with neutropenia, they
should be used with care due to the increasing rates
of carbapenem resistant gram-negative bacteria
worldwide1. Hence, non-carbapenem anti-
pseudomonal antimicrobials are recommended in
instances where the local antimicrobial resistance for
carbapenems  rates are low 1.
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Enterococci are found in the gastrointestinal
tract flora, oropharyngeal secretions, and on the skin
5. They may cause nosocomial infections in vulnerable
patients who are colonized with vancomycin resistant
enterococci (VRE) or exposure to contaminated
tools or hands of medical staff6.
Advanced age, severity of illness, inter-
institutional transfer of the patient, prolonged hospital
stay, gastrointestinal surgery, transplantation, exposure
to medical devices, especially central venous catheters,
and heavy exposure to broad-spectrum antimicrobial
drugs were reported as risk factors for colonization
and infection with VRE7. Here, we retrospectively
evaluated the FN episodes and their outcomes with
respect to modification rates of non-carbapenem-
based empirical antibacterial therapy and VRE
colonisation that proceeded to VRE bacteremia in
patients with hematological malignancies.
Methods
All consecutive patients between September 2010
and November 2011, who were older than 14 years
of age and developed FN episodes during
chemotherapy due to hematological malignancies at
the hematology department of  Okmeydaný Training
and Research Hospital were enrolled in this
retrospective and observational study.  The
hematology department was equipped with 23 beds.
The patient rooms were designed as single, double
and four-person without high-efficiency particulate
air filters. FN was defined as an oral temperature of
>38.5°C or two consecutive readings of >38.0°C
for 2 h and an absolute neutrophil count <0.5 ×
109/L, or expected count to fall below 0.5 × 109/L
1.
Collected data included patient
demographics and diagnosis, episode data, clinical
presentation and laboratory findings, clinical therapy,
microbiological data and the outcome. The treatment
protocol for FN of our hospital was based on clinical
practice guidelines for the use of antimicrobial agents
in neutropenic patients with cancer, from 2002 and
the update in 2010 by the Infectious Diseases Society
of America and European Organization for
Research and Treatment of  Cancer/Invasive Fungal
Infections Cooperative Group and the National
Institute of  Allergy and Infectious Diseases Mycoses
Study Group (EORTC/MSG) guidelines1, 8, 9.
Therapeutic regimens that were active against
Pseudomonas aeruginosa were chosen randomly in
accordance with local antibiotic resistance status. They
included piperacillin-tazobactam (PIP-TAZ) that was
administered in a dose of 4.5 g q8h by infusion,
cefoperazone-sulbactam (CEP-SUL) that was
administered in a dose of 2 g q8h by infusion, or
PIP-TAZ that was administered in a dose of 4.5 g
q8h by infusion in combination with ciprofloxacin
(CIP) that was administered in a dose of 400 mg
q12h. Ciprofloxacin was combined in patients whose
symptoms involving respiratory system
predominated. Antibacterial treatment was changed
to one of the carbapenem options; imipenem
(administered in a dose of 500 mg q6h) or
meropenem (administered in a dose of 1 gr q8h),
or other effective antibiotics against pathogens grown
in the sample culture, if they exhibited a persistent
fever after two days of empirical antibiotic therapy
or had clinical, laboratory and radiological findings.
Patients who received carbapenem
empirically (imipenem administered in a dose of 500
mg q6h or meropenem administered in a dose of 1
gr q8h) in combination with other antimicrobials at
admission or during FN attacks due to severity of
illness or history of infections caused by resistant
bacteria were recorded as well. Vancomycin was
considered for specific clinical indications, including
suspected catheter-related infection, skin or soft-
tissue infection, pneumonia, or hemodynamic
instability.
Patients who received one of the non-
carbapenem, anti-pseudomonal antibiotic in
combination with other antibiotics, were excluded
from the evaluation of response to non-
carbapenem-based therapy. Response to
carbapenem-based therapy was evaluated in patients
who received only one of the carbapenem options
without any combined antimicrobials. Fungal
pathogens and antifungal therapy were not evaluated
in this study.  Antibiotic doses were adjusted in the
cases of hepatic or renal failure.
Blood samples drawn from vein or catheter
were inoculated into BactAlert 3D bottles
(bioMérieux, Marcy-l’Etoile, France). In addition,
samples such as urine, sputum, wound, conjunctive,
abscess, and catheter were inoculated onto 5%
sheep-blood agar (Salubris Inc., Istanbul, Turkey),
chocolate agar (Salubris Inc., Istanbul, Turkey) and
MacConkey agar (Salubris Inc., Istanbul, Turkey).
Susceptibility testing was performed using an
automated broth microdilution method (Vitek 2,
bioMérieux, Marcy-l’Etoile, France) and
confirmations were made by the E test method (AB
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BIODISK, Solna, Sweden). The breakpoints defined
by the Clinical and Laboratory Standards Institute
(CLSI, 2008) were used. VRE colonisation was
screened by rectal swabs that were inoculated onto
a bile-esculin-azide agar plate containing 6 µg/mL
of  vancomycin (Becton, Dickinson and Company,
Sparks, MD, USA). Plates were then incubated
aerobically in 5 to 10% CO
2
 at 35 to 37°C for up to
48 hours (for confirmation of  a negative result).
Samples from patients were collected in two-week
intervals. Colonisation with VRE was defined as
positive culture of rectal swab until two rectal swab
cultures which were taken with an interval of  two
weeks were negative without clinical and radiologic
findings associated with VRE. The strains isolated
from cultures, which were defined as colonisation
or contamination by infectious diseases specialists or
medical microbiologists, were excluded from the
study.
Response to empirical therapy was defined
as defervescence in 48-72 hours subsequent to
initiation of antibiotic, recovery of increased levels
of C reactive protein (CRP), leukocytosis or
leukopenia, recovery of vital signs and clinical
symptoms associated with infection (improvement
in arterial blood-gas values, radiological
improvement, negative urine culture for urinary
system infection and recovery of signs and
symptoms related to other infections). Treatment
response rates of empirical antibacterial therapy
without modification and VRE infection rates of
patients colonized with VRE during the neutropenic
phase were the primary outcomes of  this study.
Mortality rates, however, were the secondary
outcomes of  this study.
Statistical analysis
Continuous variables were described as mean±
standard deviation and range. Percentile values were
described without decimals. Overall mortality
associated with FN was defined as death within 30
days after development of neutropenia. Mortality
rates were calculated as proportion of patients who
died during the neutropenic phase and due to
infection to all patients who were included in the
study. Modification rates were compared by Pearson
chi-square.  P value was set at < 0,05  for significance.
Response to non-carbapenem-based therapy was
calculated with proportion of patients who
responded to non-carbapenem-based therapy to all
patients who received a solo non-carbapenem, anti-
pseudomonal antibiotic therapy. Response to solo
carbapenem-based therapy was calculated with
proportion of patients who responded to solo
carbapenem-based therapy to all patients who
received solo carbapenem only.
Results
We retrospectively analyzed 86 consecutive patients
with neutropenia and their 151 febrile episodes. Of
the 86 patients, 45 were male and the mean age was
47,65±15,06 years (range: 17–82 years). Mean
MASCC score was 18,72 ± 9,43. The distribution
of patients’ hematological malignancies is presented
in table 1.
Table 1: Distribution of  hematologic malignancies in
the patients with febrile neutropenia (n: 86)
Hematologic malignancies n (%)
Acute myeloblastic leukemia 50 (58)
Acute lymphocytic leukemia 19 (22)
Chronic lymphocytic leukemia 5 (6)
Multiple myeloma 4 (4)
Non-Hodgkin lymphoma 2 (3)
Mantle-cell lymphoma 2 (3)
Aplastic anemia 1 (1)
Hairy cell leukemia 1 (1)
Chronic lymphocytic 1 (1)
leukemia with Burkitt’s lymphoma
Chronic myeloid leukemia 1 (1)
Bacteremia due to gram-positive and gram-negative
bacteria was developed in 30 attacks in 28 patients
(table 2). Empirical therapy with CEP-SUL was
modified to carbapenem monotherapy in 59 of 75
(79%) febrile attacks. Empirical therapy with PIP-
TAZ was modified to carbapenem monotherapy
in 16 of 22 (73%) febrile attacks. Empirical therapies
with CEP-SUL (n:13) or PIP-TAZ  (n: 4) in
combination with CIP were changed to carbapenem
monotherapy in 13 of  17 (77%) febrile attacks.  After
switching to carbapenem monotherapy, 26 of  88
(29%) patients responded to therapy (figure 1).
Among patients who received carbapenem in
combination with other antibacterials (n = 37), at
admission or during FN attacks, without
accompanying antifungal therapy, six of  them (16%)
responded to therapy (figure.1). Other attacks were
overcome with antifungal therapy. Modification rates
of both, empirical monotherapy and combination
therapy, were found similar, statistically (p= 0,840).
In total, 30 bacteremia attacks by gram-negative (n
= 24) and gram-positive bacteria (n = 6) developed
and one of six patients with extended spectrum β-
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lactamase (ESBL)-producing gram-negative bacteria
related bacteremia responded to CEP-SUL
treatment without changing to carbapenems (table
2).
Table 2: Isolated bacteria that led to bacteremia
in the patients with febrile neutropenia
Hematologic Malignancy n (%)
ESBL (+) E. coli 1 (3,3)
ESBL (“) E. coli 8 (26,7)
ESBL (+) K. pneumoniae 3 (10,0)
ESBL (“) K. pneumoniae 3 (10,0)
Pseudomonas aeruginosa 3 (10,0)
Serratia marcescens 1 (3,3)
Serratia ficaria 1 (3,3)
Citrobacter koseri 1 (3,3)
Enterobacter cloacae 1 (3,3)
Ochrobactrum anthropi 1 (3,3)
Stenotrophomonas maltophilia 1 (3,3)
MRSA 3 (10,0)
MSSA 1 (3,3)
Vancomycin sensitive  Enterococcus faecium 2 (6,7)
Total 30 (100)
ESBL; Extended spectrum beta-lactamase, MRSA;
Methicillin-resistant Staphylococcus aureus,
MSSA; Methicillin-sensitive Staphylococcus aureus
Non-carbapenem-based therapy achieved clinical
and microbiological responses in six of 24 patients
with gram-negative bacteremia. Stenotrophomonas
maltophilia which was isolated from three sputum
samples and was in concordance with radiological
and clinical findings was successfully treated with
imipenem. Methicillin-resistant Staphylococcus aureus
(MRSA) was also isolated from catheter (n = 4),
blood (n = 3) and sputum (n = 1) cultures belonged
to five patients. MRSA related pneumonia did not
respond to vancomycin therapy in a patient who
subsequently died. Methicillin-sensitive
Staphylococcus aureus (MSSA) was also isolated
from abscess (n = 2), wound (n = 2) and blood (n
= 1) cultures and CEP-SUL that was initiated
empirically for FN provided good response.
Vancomycin sensitive Enterococcus faecium was also
isolated from wound (n = 1), urine (n = 1) and
sputum (n = 1) cultures. VRE were isolated from
bronchoalveolar lavage and blood cultures in one
patient with pneumonia and dyspnea who was
admitted from another hospital. All rectal swab
cultures of  this patient yielded normal flora bacteria
during follow-up and the patient was successfully
treated with linezolid. No VRE bacteremia
developed during the 748 days of colonization in
65 patients. Only two patients who had persistent
fever accompanied with diverse clinical findings
(cough, pain in the anal region, ulcerations in oral
mucosa, etc.) responded to linezolid treatment.
Chemotherapy port catheter line and bone marrow
biopsy were performed to patients colonised with
VRE as invasive procedures during follow-up.
Overall mortality rates were 26% (n = 23)
and 17 patients died due to infections including
pneumonia, invasive fungal infections, urinary tract
infections, central line blood stream infections and
intraabdominal infections. MRSA bloodstream
infections (n = 2), candidemia (n = 5) and vancomycin
sensitive Enterococcus faecium that induced severe sepsis
(n = 1) were recorded in patients who died.
Figure 1: Response rates to non-carbapenem-based therapies and to carbapenem monotherapies
in febrile neutropenia attacks (n: 151)
CEP-SUL: Cefoperazone-sulbactam, PIP-TAZ: Piperacillin-tazobactam, CIP: Ciprofloxacin
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Discussion
Non-carbapenem-based empirical antimicrobial
monotherapy provided achievement comparable to
that of non-carbapenem-based empirical
combination therapy and also both frequently
necessitated the shift to carbapenem-based therapy
in febrile patients with neutropenia due to cancer
chemotherapy. Previous randomized control trials
and meta-analysis of randomized controlled trials
revealed that monotherapy is not inferior to
combination therapy in empirical treatment of
febrile neutropenia10, 11. However, beta-lactam
antibiotics that were initiated empirically were
switched to one of the carbapenems after two days of
treatment due to persistent clinical, radiological and
laboratory findings according to IDSA and
EORTC/MSG guidelines. Modification rates were
lower with CEP-SUL (79%) compared to PIP-TAZ
(73%) in our study. Moreover, CEP-SUL combined
with CIP (23%) was found not superior compared
to other monotherapy options (figure.1).
Carbapenems and other anti-pseudomonal
antibiotics cured half of patients with FN attacks in
monotherapy regimens. However, in one third of
the patients with FN, low treatment response was
obtained with a carbapenem combinated with
another antimicrobial. Our results suggest that
initiating of carbapenem based therapy does not
provide high response rates in the treatment of
febrile neutropenic attacks. Furthermore, non-
carbapenem-based empirical therapy provides
benefit in regard to cost-effectiveness and
antimicrobial stewardship when local antibiotic
resistance patterns of gram-negative bacteria are
considered. Patients who are colonized with VRE are more
likely to develop bacteremia with VRE strains as a result of
invasive procedures and severe damage of  mucosal barriers
observed in this group of  patients. Endogenous flora
which is predominated by gram-negative bacteria,
especially Enterobacteriaceae species in the
gastrointestinal tract, can lead to fever in patients with
neutropenia due to breakdown of mucosal barriers
secondary to chemotherapy12.
Enterobacteriaceae species were predominant
over other gram-negative and gram-positive bacteria
in our study and non-ESBL-producing E. coli and
K. pneumoniae were noted as the most common isolates
that caused to bacteremia.  Infections with resistant
gram-negative bacteria, especially with
Enterobacteriaceae species, are a big challenge
worldwide13 . Switching from non-carbapenem-
based therapy to carbapenem-based therapy was
mostly required due to increased resistance rates of
gram-negative bacteria. In a previous study, Gedik
et al. observed that fecal harboring of  ESBL-
producing Enterobacteriaceae isolates had reached a
considerable frequency in the healthy population; 5%
in Escherichia coli, 14% in Klebsiella pneumoniae and 20%
in Klebsiella oxytoca isolates14. Although overall mortality
rates for patients who received carbapenems and
for those who received non-carbapenem anti-
pseudomonal antibiotics were found similar, fewer
cases of clinical failure and lower modification rates
for glycopeptide antibiotics were reported in the
patients who received carbapenems10. There has yet
to be a randomized controlled trial for the treatment
of bacteremia with ESBL-producing
Enterobacteriaceae species comparing beta-lactam/beta-
lactamase inhibitor combinations against
carbapenems. Nevertheless, restrospective studies
revealed that treatment response rates of nosocomial
bacteremia were lower with beta-lactam/beta-
lactamase inhibitor combinations compared to
carbapenems 15-17. Furthermore, inadequate initial
antimicrobial therapy was reported to be a significant
predictor for mortality in the patients with
hematological malignancies18 . MRSA bacteremia
developed in three patients and two of them died.
For MRSA related infections, measures like
screening, decolonisation, isolation and contact
precautions for patients with MRSA should be taken,
as MRSA infections were reported to increase in
patients with FN19, 20. Patients who are admitted from
healthcare facilities or nursing homes that have high
MRSA colonization or infection rates should be
screeened for MRSA colonisation, however,
screening for MRSA is not indicated for settings with
low MRSA infection rates21, 22. Long-term catheters
that are implemented to administer chemotherapy
predispose patients to MRSA related bacteremia and
catheter infections.
VRE colonization predisposes patients to
VRE bacteremia and was reported to be a poor
prognostic factor in patients with neutropenia23.
Moreover, invasive devices, broad-spectrum
antibiotic use (vancomycin, cephalosporins, anti-
anaerobic agents) and severity of illness have been
reported as independent risk factors for VRE
infection24.
However, only mucositis or increasing
mucositis were reported as independent risk factors
for VRE-related blood stream infection23. Invasive
procedures or devices and mucositis may lead to
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VRE bacteremia in patients who are colonised with
VRE and receive high dose cancer chemotherapy.
The small number of invasive procedures in 65
patients were probably the reason for the small
number of VRE bacteremia cases developed during
748 colonization days. VRE pneumonia and
bacteremia were developed in a patient who had
negative rectal swab cultures during follow-up. In
two patients with documented VRE colonisation,
persistent fever, clinical, radiological and laboratory
findings were observed which responded to linezolid,
despite a culture-proven infection. Patients colonised
with VRE should be treated with antibiotics active
against VRE in the case of persistent fever and
hemodynamic instability under any antimicrobial
therapy as recommended in the guidelines1, 8. A large
number of patients colonised with VRE pointed
out insufficiency of contact and barrier precautions,
cleansing, and number of single-patient rooms in
our study, as well. The small number of  cases,
episodes of FN and bacteremia attacks were the
limitations of  our study.
Conclusion
Consequently, non-carbapenem-based therapy may
be cost-effective as the empirical treatment regimen
of  FN attacks. Carbapenem-based therapy should
be opted as empirical therapy depending on the
severity of  patients. VRE bacteremia is more likely
to develop in patients who undergo invasive
procedures, have severe breakdown of mucosal
barriers, and prolonged and combined broad-
spectrum antibiotics use. In hemodynamically unstable
patients who do not respond to antimicrobial
treatment, VRE colonisation should be taken into
consideration whilst shifting to other antibiotic
options.
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